Document is current
Any future updates will be listed below
-
Authors
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
Brambilla, Elisabeth
Faivre-Finn, Corinne https://orcid.org/0000-0001-5617-9781
Sage, Julien
- License Information
-
More Information
Article History
Accepted: 23 November 2020
First Online: 14 January 2021
Competing interests
: C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Ascentage, Astra Zeneca, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Lilly, Pfizer, PharmaMar, Syros and Vavotek. He serves on the scientific advisory boards of Bridge Medicines and Harpoon Therapeutics. J.S. receives research funding from Stemcentrx/Abbvie, Pfizer, and Revolution Medicines and has licensed a patent to Forty Seven Inc./Gilead on the use of CD47-blocking strategies in SCLC. E.B. and C.F.-F. declare no competing interests.
